Longevity & AgingNew NLRP3 Inhibitor Slashes Inflammation Markers by 85% in Phase 1 Trial
BioAge has released promising Phase 1 results for BGE-102, an oral drug that targets the NLRP3 inflammasome — a key driver of chronic inflammation linked to aging and disease. In a randomized, placebo-controlled trial involving healthy volunteers and people with obesity and elevated inflammation, the drug reduced high-sensitivity C-reactive protein (hsCRP) by up to 86% within weeks. Over 87% of participants on the lower dose normalized their hsCRP levels to healthy ranges. IL-6 and fibrinogen, two other inflammation markers tied to cardiovascular and metabolic risk, also declined. The drug was well tolerated with no serious adverse events. Phase 2 trials targeting cardiovascular risk and diabetic eye disease are planned for mid-2026.
